Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma

7510 Background: We reported that vaccination with melanoma-derived HSPPC-96 resulted in melanoma-specific T-cell response (50%) and in clinical response (18%) in patients with residual disease. To...